Education
About Us
Working with TipRanks
Follow Us
Lantheus Holdings Inc (LNTH)
NASDAQ:LNTH
LNTH Stock Chart & Stats
$74.91
-$2.32(-2.39%)
At close: 4:00 PM EST
$74.91
-$2.32(-2.39%)
Day’s Range― - ―
52-Week Range$47.25 - $111.29
Previous CloseN/A
Volume177.90K
Average Volume (3M)790.07K
Market Cap
$4.84B
Enterprise Value$5.41B
Total Cash (Recent Filing)$359.12M
Total Debt (Recent Filing)$738.00K
Price to Earnings (P/E)22.2
Beta0.54
Next Earnings
Apr 30, 2026EPS Estimate
1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.67
Shares Outstanding64,605,896
10 Day Avg. Volume947,462
30 Day Avg. Volume790,065
Financial Highlights & Ratios
PEG Ratio-0.82
Price to Book (P/B)4.12
Price to Sales (P/S)2.91
P/FCF Ratio12.69
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue3.51
Enterprise Value/Gross Profit5.74
Enterprise Value/Ebitda14.20
Forecast
1Y Price Target
$91.80Price Target Upside22.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)5.51
Revenue Forecast (FY)$1.49B
Bulls Say, Bears Say
Bulls Say
Product Launches And Market ExpansionAnalyst highlights that the launch of a new diagnostic and wider use of PET imaging for Alzheimer’s disease can reinvigorate top-line growth and diversify revenue exposure beyond therapeutics.
Regulatory ApprovalsAnalyst notes pending regulatory decisions for new diagnostic agents that may expand addressable markets and support future revenue growth if approvals are obtained.
Reimbursement PositioningAnalyst expects a next-generation formulation to gain transitional pass-through reimbursement, which could stabilize flagship product sales as a competitor's preferential status expires.
Bears Say
Leadership UncertaintyMultiple leadership departures, including the President and COO, introduce uncertainty around strategic execution and may weigh on investor confidence during the transition.
Pricing Pressure And Volume TrendsManagement identified ongoing pricing pressure and declines in imaging dose volumes that are likely to suppress near-term revenue and contribute to share price volatility.
Weak Near-term GuidanceAnalyst warns that guidance below consensus and delayed benefits from new product formulations push recovery into later periods, increasing execution risk for the company.
Lantheus News
LNTH FAQ
What was Lantheus Holdings Inc’s price range in the past 12 months?
Lantheus Holdings Inc lowest stock price was $47.25 and its highest was $111.29 in the past 12 months.
What is Lantheus Holdings Inc’s market cap?
Lantheus Holdings Inc’s market cap is $4.84B.
When is Lantheus Holdings Inc’s upcoming earnings report date?
Lantheus Holdings Inc’s upcoming earnings report date is Apr 30, 2026 which is in 59 days.
How were Lantheus Holdings Inc’s earnings last quarter?
Lantheus Holdings Inc released its earnings results on Feb 26, 2026. The company reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.194 by $0.476.
Is Lantheus Holdings Inc overvalued?
According to Wall Street analysts Lantheus Holdings Inc’s price is currently Undervalued.
Does Lantheus Holdings Inc pay dividends?
Lantheus Holdings Inc does not currently pay dividends.
What is Lantheus Holdings Inc’s EPS estimate?
Lantheus Holdings Inc’s EPS estimate is 1.23.
How many shares outstanding does Lantheus Holdings Inc have?
Lantheus Holdings Inc has 64,605,896 shares outstanding.
What happened to Lantheus Holdings Inc’s price movement after its last earnings report?
Lantheus Holdings Inc reported an EPS of $1.67 in its last earnings report, beating expectations of $1.194. Following the earnings report the stock price went down -0.383%.
Which hedge fund is a major shareholder of Lantheus Holdings Inc?
Currently, no hedge funds are holding shares in LNTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lantheus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$91.80 (22.55% Upside)
$91.80 (22.55% Upside)
Blogger Sentiment
Bullish
LNTH Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Bullish
Bullish news 79%
Bearish news 18%
Bearish news 18%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.12%
12-Months-Change
Fundamentals
Return on Equity
21.45%
Trailing 12-Months
Asset Growth
10.53%
Trailing 12-Months
Company Description
Lantheus Holdings Inc
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
LNTH Company Deck
LNTH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced / Neutral: The call highlighted meaningful strategic progress — acquisitions (Neuraceq, OCTEVY candidate), a broadened radiodiagnostic pipeline, strong product positions (PYLARIFY volumes, DEFINITY market share), multiple near-term regulatory milestones, and a clear commercialization plan targeting 2027 growth. However, near-term pressures are material: PYLARIFY revenue decline and pricing headwinds, gross margin compression (~289 bps YoY), Q4 cash-flow and free-cash-flow deterioration, and notable one-time integration and litigation costs. Management is taking prudent, deliberate steps (divestiture of SPECT, focusing capital on diagnostics, launch-readiness investments) which support a constructive medium-to-long-term outlook, but the near-term financial headwinds and execution/timing risks balance the positives.View all LNTH earnings summariesLNTH Revenue Breakdown
65.91% Radiopharmaceutical oncology
30.09% Precision diagnostics
4.00% Strategic Partnerships and other revenue
LNTH Stock 12 Month Forecast
Average Price Target
$91.80
▲(22.55% Upside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―
Ownership Overview
Currently, No data available
---